ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novartis Takes All Of Ofatumumab

by Rick Mullin
August 31, 2015 | APPEARED IN VOLUME 93, ISSUE 34

Novartis has acquired the remaining rights to ofatumumab, a monoclonal antibody under development for the treatment of multiple sclerosis and other autoimmune diseases, from GlaxoSmithKline. Novartis previously acquired the rights to ofatumumab for oncology and currently markets it under the name Arzerra. Under the new deal, Novartis will pay GSK $300 million up front and $200 million more following the start of Phase III trials in multiple sclerosis. GSK is eligible for an additional $534 million in milestone payments as well as royalties on commercialized drugs.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment